Intensity Therapeutics, Inc.
INTS
Rank in Stocks
#29243
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$8.51M
Change (1 day)
5.00%
Change (1 year)
-67.69%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Intensity Therapeutics, Inc. (INTS)
Category
Healthcare
EPS for Intensity Therapeutics, Inc. (INTS)
EPS as of September 2026 TTM: $-4.37
According to Intensity Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-4.37. At the end of 2025 the company had an EPS of $-8.56, an increase over its 2024 EPS of $-29.25.
EPS history for Intensity Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.37 | -48.95% |
| 2025 | $-8.56 | -70.74% |
| 2024 | $-29.25 | -15.22% |
| 2023 | $-34.50 | -37.84% |
| 2022 | $-55.50 | -4.31% |
| 2021 | $-58.00 | 31.07% |
| 2020 | $-44.25 | 12.03% |
| 2019 | $-39.50 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -458.35% |
US
|
|
| $-7.07 | 61.78% |
US
|
|
| $-5.29 | 21.05% |
AU
|
|
| $12.88 | -394.74% |
BE
|
|
| $21.56 | -593.36% |
NL
|
Questions about Intensity Therapeutics, Inc.'s earnings per share (EPS)
What is Intensity Therapeutics, Inc.'s earnings per share (EPS)?
Intensity Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-4.37, as of Sep 2026.
What was Intensity Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Intensity Therapeutics, Inc.'s earnings per share (EPS) was $-8.56, compared with $-29.25 in 2024.
How has Intensity Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Intensity Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-8.56) and lowest in 2021 ($-58.00).
How does Intensity Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Intensity Therapeutics, Inc.'s earnings per share (EPS) ($-4.37) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.